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Abstract
Background: Pragmatic randomised controlled trials (PRCTs) aim to assess intervention effectiveness by accounting
for ‘real life’ implementation challenges in routine practice. The methodological challenges of PRCT implementation,
particularly in primary care, are not well understood. The Kanyini Guidelines Adherence to Polypill study (Kanyini
GAP) was a recent primary care PRCT involving multiple private general practices, Indigenous community controlled
health services and private community pharmacies. Through the experiences of Kanyini GAP participants, and using
data from study materials, this paper identifies the critical enablers and barriers to implementing a PRCT across
diverse practice settings and makes recommendations for future PRCT implementation.
Methods: Qualitative data from 94 semi-structured interviews (47 healthcare providers (pharmacists, general
practitioners, Aboriginal health workers; 47 patients) conducted for the process evaluation of Kanyini GAP was used.
Data coded to ‘trial impact’, ‘research motivation’ and ‘real world’ were explored and triangulated with data
extracted from study materials (e.g. Emails, memoranda of understanding and financial statements).
Results: PRCT implementation was facilitated by an extensive process of relationship building at the trial outset
including building on existing relationships between core investigators and service providers. Health providers’ and
participants’ altruism, increased professional satisfaction, collaboration, research capacity and opportunities for improved
patient care enabled implementation. Inadequate research infrastructure, excessive administrative demands, insufficient
numbers of adequately trained staff and the potential financial impact on private practice were considered
implementation barriers. These were largely related to this being the first experience of trial involvement for
many sites. The significant costs of addressing these barriers drew study resources from the task of achieving
recruitment targets.
Conclusions: Conducting PRCTs is crucial to generating credible evidence of intervention effectiveness in
routine practice. PRCT implementation needs to account for the particular challenges of implementing collaborative
research across diverse stakeholder organisations. Reliance on goodwill to participate is crucial at the outset. However,
participation costs, particularly for organisations with little or no research experience, can be substantial and should be
factored into PRCT funding models. Investment in a pool to fund infrastructure in the form of primary health research
networks will offset some of these costs, enabling future studies to be implemented more cost-effectively.
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Background
Randomised controlled trials are generally seen as the ‘gold
standard’ for assessing the efficacy of health sector interven-
tions. Challenges in applying the evidence based on ex-
planatory trials of interventions tested in optimal conditions
have led to a growing emphasis for pragmatic randomised
controlled trials (PRCTs). PRCTs involve a comparison of
interventions and using health outcome measures that are
relevant to ‘real-world’ healthcare delivery. This allows for
generalisability of the PRCTs’ findings which may be more
accessible to decision-makers and thus be translated into
practice and policy [1–6]. PRCT interventions are often
multifaceted with multipurposed analyses and the provider
and the recipient of an intervention may not only be the
health professionals and patients respectively but can be
other members in the health system [2].
Designing PRCTs is not straightforward. For instance,
in primary care settings, given the broad spectrum of
disease presentation and diverse practice settings, maxi-
mising generalisability in a PRCT without overly com-
promising reliability or accuracy has proven difficult [8].
In this regard, strategies to deal with design issues such
as unblinded treatment allocation and recruiting repre-
sentative participants have been suggested [9]. More
recently, a tool of ten domains known as the Pragmatic-
Explanatory Continuum Indicator Summary (PRECIS)
was developed by Thorpe et al. as a guide for researchers
in designing PRCTs [10, 11]. The ten domains include
participant eligibility criteria, intervention and comparison
flexibility and expertise, follow-up intensity, participant
compliance and participant adherence to study protocol,
selecting and analysing primary outcomes which are rele-
vant to clinical practice [7]. It is thought that by capturing
‘real-life’ practice variation the evidence generated will be
more relevant to policy-makers [7].
The Kanyini Guidelines Adherence with the Polypill
study (Kanyini GAP) provides a recent example of a PRCT
that was implemented within Australian primary care.
Kanyini GAP sought to explore whether a strategy based
on the use of a fixed-dose combination pill (polypill),
comprising low-dose aspirin, a statin and two blood pres-
sure lowering agents, would improve patient adherence to
and provider prescribing of evidence-based cardiovascular
disease (CVD) preventive medications [12, 13]. This trial
was conducted in primary care rather than in hospitals
reflecting the setting where, in practice, prevention and
early management of cardiovascular disease is most likely
to take place [14].
Kanyini GAP included a range of diverse practice sizes
and settings across Australia: 12 Indigenous Health Services
(IHS) (which were 11 Aboriginal Community Controlled
Health Services and 1 government-run health service) and
21 private mainstream general practices. Medications were
dispensed through community pharmacies with patients in
both treatment groups required to pay for their medicines
at the prevailing co-payment rate. By incorporating these
design features, the study sought to mimic the systems
through which the comparative treatments would be deliv-
ered in practice; therefore, potentially yielding more gener-
alisable assessments of ‘real-life’ effectiveness. Figure 1
shows the organisation of the trial management between
the research coordinating centres and primary care services.
A Consolidated Standards of Reporting Trials (CONSORT)
flow diagram and checklist of this completed randomised
controlled trial (RCT) are included as additional documents
(see Additional files 1 and 2). Despite Kanyini GAP being
designed according to recommendations in the PRCT-
related literature, a number of problems were encountered
in implementation: recruitment fell considerably short of
expected targets (n = 623 c.f. 1000), challenges related to
stakeholders not having prior research experience yet re-
quired to comply with Good Clinical Practice [15], study
duration was considerably longer than expected and the
costs exceeded the projected budget.
At present, there is very little published evidence that de-
scribes the experience of implementing a PRCT in primary
care from the perspectives of the participants. To address
this gap in evidence, this paper aims to identify the critical
enablers and barriers to implementing Kanyini GAP.
Drawing on the experiences of patients and providers par-
ticipating in Kanyini GAP and key trial documentation, we
sought to make recommendations for the future imple-
mentation of PRCTs in primary healthcare settings.
Methods
This study uses qualitative data from the overall process
evaluation of Kanyini GAP [16]. A predefined protocol
for the process evaluation was used [16]. The methods
are described across the three domains as specified in
the consolidated criteria for reporting of qualitative
studies developed by Tong et al. from a review of estab-
lished guidelines and qualitative studies [17].
Research team and reflexivity
Study investigators (TU, SJ, JR, TL, DP, and AC) who
were involved in the design and implementation of
Kanyini GAP developed the interview guides which
were iteratively revised to explore themes and issues
emerging from earlier interviews. Views about the poly-
pill strategy in CVD management, patient satisfaction
or problems with the polypill, issues regarding trial im-
plementation, and perspectives of translation of the
polypill into clinical practice were key domains of the
interview guides. The interviews were conducted by a
team of seven interviewers. Two of the interviewers
had existing relationships with some of the participants
interviewed as they were research coordinators in the
trial but the other interviewers were not known to the
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participants prior to the interviews. The team had diverse
backgrounds (health economics, nursing, pharmacy, Indi-
genous health), varied experience in qualitative research
and three were Indigenous and four non-Indigenous
researchers.
Study design
Site recruitment for the Kanyini GAP trial was initiated
with the general practitioners (GPs) of private practices
and IHSs, as well as the board members of IHSs. A
critical enabler to the recruitment of GPs was the
extensive process of undertaking relationship building
and leveraging existing networks amongst Kanyini
GAP chief investigators. In particular, prior to Kanyini
GAP, a relationship between the research-team and
several of the IHSs existed as part of the Kanyini
Vascular Collaboration – a chronic disease-based re-
search collaboration between the two research insti-
tutes and participating IHSs around Australia.
Participants were purposively recruited for the qualita-
tive study from these participating Kanyini GAP sites
based on maximum variation of specified variables
which were based on adherence literature which may
affect participants’ experience with a polypill-based strat-
egy and also variables which may impact trial implemen-
tation. We used the sampling matrix to select patients
based on these characteristics; for patients these were
location, age, gender, ethnicity, primary versus secondary
CVD, and self-reported adherence at baseline; and for
providers variables included location and profession
[18]. All health providers and patients were sent an invi-
tation letter outlining the study and its objectives, and
followed-up by a phone call by the project coordinator
(LM). Five patients declined to be interviewed and two
patients were not available, and all health providers
agreed to be interviewed. Written informed consent was
obtained from all participants.
Most face-to-face interviews, which ranged from
30 min to an hour, were conducted either at home or at
the health service, and audio-recorded. Two participants
from interstate were not available for a face-to-face
interview. Phone interviews were conducted with these
two participants and audio-recorded. One researcher
LM was involved in almost all the interviews to ensure
consistency [18]. She conducted 40 with another inter-
viewer and 42 alone. LM coordinated the study and was
trained in qualitative methods. She conducted prelimin-
ary thematic data analysis alongside the interviews. The-
matic saturation was achieved and interviews stopped.
Analysis
Interviews were professionally transcribed. At the com-
pletion of all the interviews, two researchers (HL and
LM) used NVivo 9 (QSR International, Melbourne, VIC,
Australia) to code and manage the qualitative data.
Using the constant comparative method [19], these re-
searchers coded line by line the same twelve transcripts
independently (six patients and six health providers
across the variables) through three iterative stages and
an initial coding framework was developed. Insights
about the local setting, context of the interviews and
empirical results of the PRCT were documented and
used to aid interpretation and triangulation [20, 21]. The
overarching coding framework (which is included as an
Additional file 3) was developed for provider and patient
interviews and refined with the study investigators and
the interview team. This included two IHSs clinicians
(TU and DP) who were site principal investigators on
Fig. 1 Organisational structure of the Kanyini GAP study. Kanyini GAP was conducted in 33 sites across urban, rural and remote Australia and
recruited 623 patients through 12 Indigenous health services and 21 private general practices. There was one central coordinating centre based
in Sydney and two regional coordinating centres based in Alice Springs and Victoria, which recruited and coordinated the sites in NSW,
Queensland, Victoria and the Northern Territory. Each ‘site’ included either a general practice clinic or an Indigenous health service and 1–3
community pharmacies
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the trial and provided respondent validation [20]. The
two researchers (HL and LM) coded the remaining
interviews equally, drawing up memos for each interview
to provide additional context for other researchers ana-
lysing the data, and recoded the original twelve inter-
views. Minor, iterative changes to code definitions were
made. An audit trail was kept.
To address the aims of this study, provider and patient
experiences that were related to trial implementation
which were coded to: ‘trial impact’ and ‘research motiv-
ation’ and ‘real world’, were explored.
Additionally, some triangulation of findings was obtained
through a review of existing Kanyini GAP documents (e.g.
Email communications, Memoranda of Understanding, and
financial statements) [17].
The study was approved by 7 regional committees
including 1 Aboriginal-specific committee jurisdiction
(Sydney South West Area Health Service (HREC Ref.
08/RPAH/126); Aboriginal Health and Medical Research
Council of NSW (642/08); Cairns Base Hospital (HREC/
08/QCH/10-546); Princess Alexandra Hospital Centres
for Health Research (HREC/08/QPAH/160); Central
Australian Human Research Ethics Committee (2008.09.
04); Northern Territory Department of Health and Menzies
School of Health Research (HREC 2010–1466; Monash
University Human Research Ethics Committee (CF09/
2353 – 2009001370)).
Results
At the end of Kanyini GAP, 94 semi-structured inter-
views were conducted by the interview team with 47
providers (25 GPs, 13 pharmacists, 6 Aboriginal health
workers (AHW) and 3 chronic care nurses) and 47
patients in NSW, Queensland and Victoria. There were
22 and 25 patients who were in the polypill arm and
usual care arm, respectively. There were 26 non-
Indigenous patients and 21 Indigenous patients.
The critical enablers and barriers to implementing this
PRCT in Australian primary healthcare settings were
broadly grouped within three key themes: recruitment
and participation; research and primary practice settings;
and participant costs. Tables 1 and 2 summarise the
identified barriers and enablers to conducting a primary
care PRCT within these three key categories and pre-
sents suggested strategies to overcome barriers and




The recruitment process for enlisting sites included a num-
ber of initial meetings, workshops and dinners to introduce
the trial and elicit expressions of interest. This approach
proved an effective way to develop and strengthen existing
relationships with primary care services. Kanyini GAP also
built upon previous research done with the IHSs, which
found a gap in the prescribing of indicated CVD medi-
cations; thus site recruitment to Kanyini GAP was seen
as a ‘natural progression’ (Provider 47, AHW). This is
evident from the following comment from a GP based
at an urban IHS:
‘The other thing that was really helpful was the way
the service was engaged by The George Institute so
that the community all knew about polypill. They’d
engaged with the Board very well, the Board and the
service had agreement so the CEO and the manager
in the service knew about it. They’d held a launch
day at the service and people were asking questions,
so there was a lot of engagement, a lot of patients
knew about it, so there was general awareness.’
(Provider 8, GP)
Some participating GPs envisaged tangible benefits to
their practice through involvement in primary health-
care research, in terms of quality improvement and staff
morale. As a GP at an urban private practice site
describes:
‘Philosophically I like the idea as a practice being
opened up to researchers …… I’ve done a lot of quality
improvement with practices and one of the things that
builds the team is opening it to the outside world.
And, participating in research is a way of opening it to
the outside world, so it’s actually a plus for team
building. Practices feel proud that they’re actually
working at this level.’ (Provider 1, GP)
In addition to staff morale, a collective increase in
research capacity at the health service level was thought
to be a positive impact of participating in primary care
research, as one GP from an urban IHS noted:
‘It was good for our research capacity, it was a project
we all believed in and got behind. … our name came
up just on the weekend at the conference that I was
at … people mentioned that we were part of the
Kanyini GAP trial. So I think from that point of view
it was good for our health service, good for our
reputation. … participating in research I think was a
good experience for those workers some of whom were
Aboriginal, so that’s increasing the research capacity,
Indigenous research capacity for (the) clinic which is
a good thing.’ (Provider 33, GP)
Providers’ research motivation
Motivation to take part in the research study was fre-
quently mentioned, with many providers stating that
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being part of a trial is for the ‘greater good’. The follow-
ing GP from an urban IHS outlined her motivation to
take part in investigator-led research:
‘I really liked and felt comfortable and trusted the
Kanyini polypill … that it was put together on the
basis of what was going to be best for people with
Table 1 Strategies to overcome barriers to implementing primary care pragmatic randomised controlled trials
Barriers Strategies to help overcome
Recruitment and participation
Prescriber disagreement about recruitment across sites:
clinical eligibility compared to trial suitability
• Prior to implementation, identify potential sources for disagreement, provide examples
and workshop solutions with providers
• Throughout recruitment, facilitate a forum for providers to discuss with research team
actual difficulties encountered
Potential negative impact of evaluated intervention on
provider’s business revenue
• Identify and discuss potential impacts (immediate and long-term) with providers;
• If possible, ensure lost revenue adequately compensated
• Educate potential providers about the value of the intervention to public good
Highly mobile patients • Consider provision of mobile recruitment services
Research and primary practice settings
Inadequate research infrastructure • Ensure adequate physical space available for trial processes
• Understand information technology (IT) capacity at sites and use study systems that
can integrate with pre-existing IT, thus minimising training requirements
• Consider using data extraction tools to minimise access time to information
technology systems
• Ensure adequate remuneration to participants for time and service provided
• Consider provision of dedicated research coordinator at sites, particularly those already
understaffed
Pre-existing workforce strains • Adequately understand workforce-related issues at participating sites
• Ensure adequate personnel support is available and can respond to high staff turnover
• Ensure adequate training at practice level, and refresher training available and
budgeted for
Potential miscommunication across multidisciplinary health
services beyond primary care
• Provision of simple communication tools at the patient and practice levels that
highlight patient involvement within the trial.
• Adequately educating patients and carers regarding about trial and need for
communicating to all healthcare providers
• Identify participant multidisciplinary providers at enrolment and target trial
communication strategies accordingly
Increased administrative burden relative to health service
delivery and patient care demands
• Provide adequate research support to sites that can minimise administrative burden
• Consider automated procedures that ensure Good Clinical Practice compliance and
can integrate with current health service processes
• Ensure site service delivery requirements are fully understood prior to implementatin
• Provide clear education about Good Clinical Practice
• Practice requirements and administrative needs prior to recruitment
Costs
High trial running costs • Ensure adequate budget for provision of research support personnel at sites to
maintain recruitment timelines, ease administrative burden to sites and reduce
opportunity cost to sites
• Additional funding load to accommodate inadequate primary care research
infrastructure
• In medium to long term establish a funding pool to invest in primary healthcare
research infrastructure
Opportunity cost to participants • Understand potential costs to participants prior to implementation
• Provide adequate remuneration to participants in light of actual time required for
administration, including time spent with research nurses
• Ensure simple processes for sites to apply for and receive remuneration
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cardiovascular disease rather than the profit motive
which pharmaceutical companies have to go by
because they’re private companies and have
shareholders.’ (Provider 33, GP)
Many of the pharmacists participated because they
were interested in the intervention under evaluation.
Several were candid about the potential negative effect a
polypill strategy could have on their revenue. As
described by a pharmacist in an urban site based close
to an IHS:
‘Now I’m aware of different critical remarks among
community pharmacists … instead of three or four
dispensing fees we see one … not being a pharmacy
owner … I’m less sensitive to that issue … By and large
it’s good for customers, it’s good for compliance, it’s
good for the government I suppose.’ (Provider 15,
Pharmacist)
For some, participating in a trial was also thought to
create an opportunity for health professionals and ser-
vices to improve the care given to patients while pro-
moting collaborations with other organisations, as this
next Aboriginal health worker from a remote IHS
described:,
‘I’d say well it gives them (the health service) the
opportunity to give their patients the best possible care
that they can … offer this one more thing (that) can
actually influence a lot of the patients that we have.
So that offers better care for our patients. But then,
you know, helping out studies also yields partnerships
with people, other organisations.’ (Provider 41, AHW)
Recruitment of patients
Patient recruitment in the pragmatic trial required sub-
stantial effort due to the diversity of the health services
and broad characteristics of patients expected to partici-
pate. For instance, recruitment in remote services was
particularly challenging given patient populations were
highly mobile and health considerations complex. A GP
in a remote IHS described it as such:
‘I think there's a difference between being eligible and
suitable, so I think that was something that wasn't
really teased out properly. We got, I think, nearly close
to our target, because we recruited a lot of eligible
Table 2 Strategies to maximise enablers to implementing primary care pragmatic randomised controlled trials
Enablers Strategies to help maximise
Recruitment and participation
Leveraging pre-existing networks and relationships with key
stakeholders
• Provide adequate pre-recruitment engagement with stakeholders and elicit
expressions of interest
• Engage with stakeholders at trial-design stage to build a sense of ownership and
address research objectives of participants
Increased research capacity • Understand research needs of sites and fulfil gaps in research capacity as requested
• Incorporate capacity building as a key outcome for participation
• Provide opportunity for training at health service level to build research capacity
within primary healthcare.
Research as a quality service indicator and team building
exercise
• Provide structured training for sites as a means for team building between and
across sites
• Research participation as a quality assurance indicator for primary practices: policy
development consideration
Professional support for the intervention under evaluation
and tangible benefits to the service or participant
• Understand and address professional concerns about the intervention under
evaluation
• Promote the potential benefits of trial participation to health service and
participants
Personal and community benefits research participation • Understand and promote benefits (and risks) of research to individuals and
community
• Educate participants about research goals and needs
• Ensure participants feel sufficiently empowered to make decisions about ongoing
participation
Research and primary practice settings
Provision of research coordinator • Prior to implementation, proactively identify site resource needs in terms of trial-
related administration, communication, data management and patient management
• Ensure adequate research and logistical support is provided
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patients. In terms of suitability, I don't know whether
we really picked patients that were appropriate for a
trial.’ (Provider 40, GP)
Moreover, for this next GP, describing the recruitment
of patients with complex comorbidities from private
practice, the broad patient eligibility criteria proved a
source for disagreement between prescribers about
recruitment:
‘I was surprised that some of the patients, who others
had been happy to put on it because when we looked
at the problems that some had, I thought, well I
wouldn’t have put that person in, in the first place…
Because they hadquite a complicated history and
potential risks of having some problems … I wanted
them to either fit in clearly or not … So I suppose I
was looking for people who didn’t really have lots of
other comorbidities … I would have said, “They’re not
suitable”.’ (Provider 36, GP)
Patients’ research motivation
For patients, an overwhelmingly positive response to be-
ing involved in the trial was expressed with many claim-
ing they were happy to be involved as ‘guinea pigs’ and
to play a part in contributing to ‘finding a cure’. Taking
part in the trial was thought to not only offer potential
benefit to them as individuals, but to others as well, and
Aboriginal and Torres Strait Islander people in particu-
lar expressed their interest in the trial for this reason:
‘You know there’s something you’re contributing to,
and it’s not just about you; it’s about how it might help
the rank and file right across the nation … if I can
help my people live longer, live better lifestyles,
healthier lifestyles, then I want to be a part of that. I
just want to be part of that group that does that.’
(Patient 10, urban IHS)
This ‘big picture’ thinking translated to a willingness
to be involved, to trust in the health system and a sense
of doing something meaningful for others even if there
were no evident or immediate benefits for themselves:
‘I don’t have a problem with studies. I think if it’s
going to ultimately benefit mankind, I'm happy to sort
of be a bit of a guinea pig. It’s an interest. It’s also a
possibility that I will suffer better health because of it,
so I don’t have a problem with those types of things
generally.’ (Patient 16, of private GP)
‘Well I did feel an obligation not to withdraw and I
don’t know how many people in your control group
stuck it out to the end but you need a certain number
to you know, validate the statistics … But I never felt
any pressure, I was always assured that I could pull
out at any time if I’d had enough. But the pressure
came from within, you know… I’ve started I should
finish.’ (Patient 25, of private GP)
Research and primary practice settings
Research infrastructure
Overwhelmingly, providers cited inadequate infrastruc-
ture as a substantial barrier to trial implementation. In-
frastructure considerations included: physical space to
conduct patient visits, access to information technology
systems, and storage space for additional supplies of
polypill (for post-trial provision of polypill to partici-
pants). Time, money and human capacity were other ne-
cessary resources which were reported as being limited.
A pharmacist in a remote area described such
challenges:
‘… I guess from our perspective, and it came down to
not necessarily The George Institute, but it was more
our settings and our dispensing program and also staff
education as well …’ (Provider 42, Pharmacist)
Research and logistical support
The provision of a research coordinator at the study
sites was described by many providers to be a key facili-
tator to trial implementation. In IHSs, the research
nurse provided logistical support for the trial through
trial-related communication with health service staff
members, administration, obtaining informed consent,
and data collection. This is evident in the following com-
ment from a GP at an urban IHS:
‘I think it has been a good thing. It's not an added, the
admin, the workload doesn’t add on because we have
the team for support here. So in that way it wasn’t
even, didn't even notice. And it's just like any other pill
really, just prescribe it. It was easy enough; it was
already on our system so we just prescribe it just like
any other.’ (Provider 5, GP)
A GP and medical director in an urban private prac-
tice also thought that the research nurse facilitated the
conduct of the study and, therefore, alleviated the effort
required from the GPs in her service:
‘… she (research nurse) facilitated everything
brilliantly. … we cringe sometimes when people ask us
to do studies in a busy general practice … without the
nurse it would have been a nightmare really, … Well, I
think the whole study would not have worked without
her, and I think it’s a real lesson for any GP research is
having a research nurse is key.’ (Provider 12, GP and
Medical Director)
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Workforce-related issues
Some sites with particularly large patient loads, long
clinic waiting times and many rotating GPs faced chal-
lenges due to potential for miscommunication between
providers, and a lack of general understanding of the
study across the service. Integrating the intervention
within the realities of a dynamic workforce and chronic
staff shortages was particularly difficult. For instance, at
some IHSs, the research coordinator position proved to
be difficult to replace as required, due to a complicated
trial coordination handover and the need for staff
re-training. A medical director of an IHS describes the
effect of high staff turnover on trial conduct:
‘I think it was more good fortune than anything else
that we actually made it to the finishing line to tell
you the truth … staffing’s been a problem the whole
way through really. I think we’ve actually had about
three or four sort of individuals that have been
identified as actually the local supports or go-to people
for the trial … within a period of 18 months, 2 years.’
(Provider 46, Medical Director)
It was also acknowledged that this problem was likely
compounded by the ongoing problem of workforce re-
tention in remote settings.
Administrative demands of clinical trials
The paperwork requiring compliance with Good Clinical
Practice guidelines, including the reporting of adverse
events, was highlighted by some GPs as being an un-
acceptable additional workload. As one GP in private
practice stated:
‘“It’s the paperwork (that) has driven me crazy … I
don’t see any future for research if that’s the amount of
paperwork you’ve got to see, … I can understand why
you’ve got to do it but it’s just insane and I think
people who design these things and make the rules
ought to go and have a good hard look at themselves
and say you know, this is stupid … Now you know,
adverse reactions are important but you know, most of
them are rubbish, most of them have got absolutely
nothing to do with the study.’ (Provider 10, GP)
When asked about future involvement in a PRCT, this
GP in an urban setting was negative about his experi-
ence, questioning the feasibility of doing ‘research on
people in the “real world” … properly’, (Provider 10, GP).
This scepticism was based on the trial’s administrative
demands competing with his fundamental priority of
adequate service delivery and patient care.
In contrast, some providers did not find the additional
paperwork overly burdensome, acknowledging time was
required to be spent on training and administrative
paperwork as a condition of committing to trial
participation.
Multidisciplinary care beyond primary care
Another area of difficulty identified with implementing a
trial in primary care settings was that it involves patients
who require multidisciplinary care that may be received
outside of the primary care sites involved in the trial. In
particular, difficulties with communicating information
about the trial between primary and secondary healthcare
was described to potentially impact patient retention, as
this next GP stated:
‘… a person that goes in and out of hospital. In which
case I think it just caused a stress. Because they’d go in
and then they’d have all of the interns and then the
residents and registrars and everybody … What is this
thing and what are you on, … And how do we, and
what do we do and how we got to change this? So I
had a couple of times when patients would actually
come and just felt that it was too difficult because of
their multidisciplinary care.’ (Provider 3, GP)
Although extensive efforts were made to inform stake-
holders about Kanyini GAP at the outset (e.g. informing
specialists about the study prior to commencement,
explaining the polypill within referral letters and providing
information cards to patients), and these were described by
providers as an essential ‘safeguard’ against miscommunica-
tion, the above finding suggests that such measures may
not have been sufficient.
Participant costs
Participants did not indicate that the incentive payments
provided for participating in the Kanyini GAP trial influ-
enced their involvement in the study, suggesting that the
altruistic motivations outlined earlier were primarily
considered. Furthermore, not all pharmacies claimed
their entitlement offered to support the dispensing and
handling of the polypill. Some pharmacists reported the
‘small’ payments were not worth the time and effort
involved in preparing the necessary paperwork.
Despite our measures to minimise the financial impact
through a remuneration of AUD$100 per patient rando-
mised into the trial, a number of GPs from private
clinics did highlight that the time involved in taking part
in the trial carried a significant opportunity cost. The
following comment from a GP, who was a private prac-
tice proprietor located outside an urban area, indicates
that even with the provision of a research nurse, partici-
pation resulted in an opportunity cost:
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‘You run a business, you really can’t, (take that much
time out), and even so we still spent quite a bit of time
with (the research nurse)… I don’t know how many
appointments we missed because of time with her even
though it wasn’t huge, it adds up.’ (Provider 37, GP
and private practice owner)
Discussion
Summary
By exploring provider and patient experiences from
Kanyini GAP, and relevant trial materials, our analysis
has revealed considerable barriers to implementing a
PRCT in primary care. Specifically, a substantive lack of
research infrastructure, limited numbers of primary care
personnel adequately trained in the conduct of clinical
trials, administrative burden from regulatory require-
ments that exceeded the demands of adequate patient
care provision and the lack of coordination across all
providers involved in the treatment of patients, including
non-primary healthcare providers, substantially impeded
implementation. Additionally, the ongoing problem of
an under-resourced primary care workforce meant that
centrally employed research nurses were needed to sup-
port the sites. As a consequence of these barriers, fund-
ing for this study – around AUD$5 million and sourced
from multiple sponsors – ultimately proved insufficient.
As a result, recruitment timelines were longer than
anticipated and ultimately targets were not met.
Despite these shortcomings, participating in Kanyini
GAP was generally considered a positive experience
with mutual benefits stated for patients and providers
involved. Benefits included professional satisfaction,
increased collaboration between the different health ser-
vices involved, improved research capacity and the oppor-
tunity for health services to improve patient care. In
addition, patients and providers participated for altruistic
reasons, being particularly motivated by the chance to
contribute to the ‘greater good’. The success of completing
Kanyini GAP appears largely attributable to an upfront in-
vestment to build and maintain collaborations across the
diverse range of Australian primary healthcare settings
and, notwithstanding the additional financial cost in-
curred, from an intensive level of research support
provided to participating sites.
Recruitment challenges in PRCT
The challenges of meeting recruitment targets particularly
within PRCTs have been well-documented [9, 22–24]. A
meta-analysis of interventions to promote patient recruit-
ment to primary care concluded that organisational char-
acteristics, especially trial infrastructure, were important
[23]. Similarly, our findings indicate that a lack of such
research infrastructure in Australian primary practice con-
tributed substantially to recruitment delays. However, the
high level of research motivation reported from both pro-
viders and patients that was underpinned by a sense of
altruism facilitated recruitment.
Some design features of Kanyini GAP, classified with
the PRECIS tool as more pragmatic than explanatory,
presented further challenges to recruitment and imple-
mentation. Specifically, the ‘participant eligibility criteria’
domain was highly flexible in Kanyini GAP such that all
patients with the condition of interest were considered
eligible [10, 11]. Using these criteria to assess site feasi-
bility on the basis of predicted recruitment targets led to
an overestimation of participant numbers compared to
what could be achieved in practice. Furthermore, the do-
main ‘experimental intervention practitioner expertise’
allowed for a full range of practitioners to apply the
intervention within the clinics [10, 11]. In larger sites
that had multiple staff on rotation, more training and
logistical support for practitioners was required through-
out the time frame of the study than might have
occurred if selected personnel were responsible for
applying the intervention. Collectively, these pragmatic
design features of Kanyini GAP meant there was a need
to engage more sites, extend study timelines and
increase expenditure to try and meet recruitment tar-
gets. However, the use of these pragmatic criteria is
necessary as they allow for real practice variation and an
assessment of the acceptability and generalisability of
the intervention.
Challenges unique to trial implementation in a primary
care setting
Our study has identified some additional challenges
which may be unique to the conduct of a clinical trial in
the primary care setting. First, in contrast to research
traditionally conducted in public healthcare facilities, a
number of primary healthcare providers in Kanyini GAP
were operating in the private sector. Although altruistic-
ally motivated to participate, the impact of the trial on
revenue and time was an important consideration. Fur-
thermore, despite establishing PRCT research partner-
ships that would now be classified as ‘best practice’, (e.g.
site feasibility pre-assessment, stakeholder involvement
and integration into usual practice workflow) [25], these
efforts were insufficient to mitigate the burden that was
experienced by some Kanyini GAP providers. In this
regard, identifying and discussing the immediate and
long-term financial impact of the trial with the health-
care providers is important at the outset. Compensation
for such costs needs to be built into existing funding
models for pragmatic trial research.
Second, as most primary care sites in Kanyini GAP
were independently owned, there was substantial vari-
ation in the day-to-day operation between sites. Chronic
staff shortages and high staff turnover were problematic,
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particularly at rural and remote sites where some of the
most disadvantaged and difficult-to-reach patients res-
ide. To enable the streamlined integration of the trial
with usual primary care processes, the provision of in-
tensive research support is needed via trained research
nurses. Research conducted in greenfield sites, involves
significant investment to increase their research capacity
for future studies.
Strengths and limitations
This study has identified enablers and barriers to the
conduct of a PRCT in Australian primary healthcare set-
tings by directly considering the experiences of partici-
pants. This information is vital for clinical researchers
who seek to generate ‘real-world’ evidence to bridge the
significant gaps known to exist between the controlled
trial environment and practice. However, this study did
not include the remote Central Australian sites involved
in Kanyini GAP. Thus, the generalisability of the study’s
findings to such sites, and to other healthcare systems
cannot be certain. So as not to influence the adherence
behaviours of participants, interviews could not be con-
ducted until the end of study. Invariably, the opinions of
participants who had dropped out of the trial prior to
the end-of-study visit, or sites that were approached but
declined to participate, could not be ascertained. How-
ever, the rigorous methods used in this study, particu-
larly triangulation of data sources, using more than one
interviewer and coder, and the breadth of clinical and re-
search experience of the research team favour robust
results.
Conclusions
A number of key recommendations for the implemen-
tation of future PRCTs in primary care have emerged.
First, significant investment in primary care research
infrastructure is needed to facilitate recruitment and
successful trial completion. Information technology sys-
tems that streamline data capture relating to key out-
comes (e.g. hospitalisation and mortality) and that can
promote communication across the various health sys-
tem levels (e.g. primary and secondary care) is one
suggestion.
Second, building research capacity within primary care
is essential. Including research as a key performance or
quality assurance indicator may increase research cap-
acity, albeit indirectly. The increased exposure of pa-
tients and practitioners to research may ultimately lead
to PRCTs being viewed as a standard feature of high-
quality primary healthcare services. This is congruent
with experiences of other PRCT trialists which found
that conducting PRCTs has the potential to achieve
greater partnerships between researchers and healthcare
systems to produce high-quality studies to improve
health-care [25].
A final strategic recommendation would be sustained
funding for adequately resourced primary care research
networks, incorporating private practices, ACCHSs
and pharmacists. Based on international evidence [26],
practice-based research networks (PBRN) are now
starting to emerge in Australia but are currently poorly
funded [27].
Notwithstanding the development of such networks,
sufficient resourcing must be set aside for individual
projects to cover the full costs of involving large num-
bers of disparate stakeholders in research. It is important
to recognise that the high unbudgeted costs in the
Kanyini GAP trial were to accommodate the lack of
research experience and training in primary care. Sub-
stantial costs associated with running trials in primary
care settings are incurred upfront, particularly when
partnering with numerous centres which have had lim-
ited or no research experience. Such upfront costs
should include not only costs to the study but the bur-
den to the individual centres for which, as uncovered in
our interviews, was often uncompensated for.
By initiating research across a numerous set of diverse
sites, Kanyini GAP has cleared paths for easier and less
costly implementation of future Australian primary care
PRCTs. A key recommendation from this project, there-
fore, is that recognition of such path-clearing investments
is required and that provision either be made (in the short
term) for loadings on research funding for new projects
that specifically set out to perform similar roles or (in the
medium to long term) the creation of a general invest-
ment pool to fund primary care research infrastructure.
Such initiatives will encourage investment in capacity that
will contribute to a broader research environment more
conducive in the long run to the running of much-needed
PRCTs.
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